The Australian market is experiencing a challenging period, with a significant downturn influenced by global market pressures and recent tech selloffs. Despite the turbulence, investors often seek ...

Viewing insider transactions for Aroa Biosurgery Limited's (ASX:ARX ) over the last year, we see that insiders were net buyers. This means that a larger number of shares were purchased by insiders in ...

Soft tissue regeneration company Aroa Biosurgery Limited has this week launched a new product named Myriad Morcells™, a morcellized (powder) format of Myriad Matrix™ that easily conforms to optimize ...

AROA lifts after recording its second consecutive quarter of positive cash flows from operations Full-year FY25 guidance remains unchanged at NZ$81-$84 million in total revenue Sales of AROA’s ...

AUCKLAND, New Zealand, Jan. 17, 2025 /PRNewswire/ -- New Zealand headquartered soft tissue regeneration company Aroa Biosurgery recently announced the publication of further strong clinical evidence ...

AUCKLAND, New Zealand--(BUSINESS WIRE)--Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, ‘Aroa’ or the ‘Company’) commences trading on the Australian Securities Exchange (ASX) today ...

Aroa Biosurgery product revenue up 27% to NZ$39.1 million on constant currency basis in H1 FY25 Myriad sales surge 45% in H1 FY25, accounting for 38% of total sales and 72% of direct sales mix during ...

AROA’s Solar Tulip is firstly a unique, if not elegant looking concentrated solar power tower which was very much designed to look less jarring in the landscape. The Israel-based company’s lead design ...

Aroa was up about 7% earlier on Tuesday, after recording its second consecutive quarter of positive cash flows from operations and reconfirming full-year FY25 guidance. AROA lifts after recording its ...